Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. by Filipits, M et al.
 1 
Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab 
treatment in HER2-positive early breast cancer: a TransHERA study 
 
Martin Filipits PhD
1
, Urania Dafni ScD
2
, Michael Gnant MD
3
, Varvara Polydoropoulou MSc
2
, 
Margaret Hills
4
, Astrid Kiermaier PhD
5
, Evandro de Azambuja MD
6
, Denis Larsimont MD
6
, 
Federico Rojo MD
7
, Giuseppe Viale MD
8
, Masakazu Toi MD
9
, Nadia Harbeck MD
10
, Kathleen I 
Prichard MD
11
, Richard D Gelber PhD
12
, Phuong Dinh MD
13
, Dimitrios Zardavas MD
14
, Brian 
Leyland-Jones MBBS
15
, Martine J Piccart-Gebhart PhD
6, 14
, Mitch Dowsett PhD
4
 on behalf of 
the TransHERA investigators 
 
1
Departments of Medicine I and 
3
Surgery, Medical University of Vienna, Comprehensive Cancer 
Center, Austria; 
2
Frontier Science Foundation-Hellas, Greece; 
4
The Royal Marsden Hospital, 
United Kingdom; 
5
Oncology Biomarker Development, Genentech, Switzerland; 
6
Institut Jules 
Bordet, Université Libre de Bruxelles (U.L.B), Belgium; 
7
Pathology Department, University 
Hospital “Fundacion Jimenez Diaz”, Spain; 8University of Milan, European Institute of 
Oncology, Italy; 
9
Department of Surgery, Kyoto University, Japan. 
10
University Hospital 
Munich, Germany; 
11
Sunnybrook Odette Cancer Centre, Toronto Sunnybrook Regional Cancer 
Centre, Canada; 
12
Department of Biostatistics and Computational Biology, Dana-Farber Cancer 
Institute, Harvard Medical School, Harvard TH Chan School of Public Health and Frontier 
Science and Technology Research Foundation, USA; 
13
Westmead Hospital, University of 
Sydney, Australia; 
14
Breast International Group (BIG), Belgium; 
15
Avera Cancer Institute, USA. 
 
  
 2 
Correspondence to: Martin Filipits, PhD 
Institute of Cancer Research 
Department of Medicine I 
Comprehensive Cancer Center Vienna 
Medical University of Vienna 
Borschkegasse 8a, A-1090 Vienna, Austria 
Phone: +43 1 40160 57528 
E-mail: martin.filipits@meduniwien.ac.at 
 
Running title: Biomarkers in HER2-positive early breast cancer 
 
Key words: HER2-positive early breast cancer, trastuzumab, predictive biomarkers, CDK 
inhibitors, cell cycle 
 
Funding: The HERA study was funded and sponsored by Hoffman-La Roche.   
 3 
Conflict of interests 
 
MF reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck 
Sharp & Dohme, Novartis, Ratiopharm, and Roche. MG reports grants and personal fees from 
Accelsior, AstraZeneca, Celgene, GlaxoSmithKline, Novartis, OBI Pharma, Pfizer, and Roche. 
AK is an employee and reports personal fees from F Hoffmann-La Roche. EdA reports grants 
and personal fees from Genentech/Roche. GV reports personal fees from Astellas Pharma, 
AstraZeneca, Bristol-Myers Squibb, Celgene, Dako, Genentech, MSD Oncology, and Roche. NH 
reports grants and personal fees from Agendia, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, 
Eli Lilly, Genentech, Genomic Health, NanoString Technologies, Novartis, Pfizer, Roche, and 
Sandoz. KIP reports personal fees from Amgen, Eisai, Novartis, Pfizer, and Roche. RDG reports 
grants from AstraZeneca, Celgene, Ferring, Ipsen, Merck, Novartis, Pfizer and Roche. DZ 
reports grants from Genentech, Novartis, Pfizer, Roche, and Tesaro. MJP-G reports grants and 
personal fees from Genentech and Roche. MD reports grants and personal fees from 
AstraZeneca, Genetech, Genoptix, GTx, Jansen Oncology, Myriad Genetics, Novartis, Pfizer, 
Radius Health, and Roche. UD, VP, MH, DL, FR, MT, PD, and BL-J declare no potential 
conflicts of interests.  
 4 
Translational relevance 
 
Patients with HER2-positive early breast cancer benefit from treatment with anti-HER2 therapies 
but long-term follow up indicates that a significant proportion of women will experience 
recurrence of their disease. Identification of predictive biomarkers may help identifying those 
patients most likely to benefit from adjuvant trastuzumab. In the TransHERA study, we observed 
a significant interaction between p27 and treatment, independent of known prognostic 
clinicopathological variables. Patients with HER2-positive early breast cancer with low p27 
expression in their tumors benefited from trastuzumab treatment whereas patients with high p27 
expression did not. This finding may help to optimize the adjuvant treatment of patients with 
HER2-positive breast cancer in the future. 
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Abstract 
 
Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell 
cycle regulation or proliferation in HER2-positive early breast cancer patients. 
Methods: Protein expression of TOP2A, Ki67, cyclin D1 and p27 was immunohistochemically 
determined in tissue microarrays of surgical specimens from 862 patients randomized to 
trastuzumab (1 or 2 year; N=561) and observation (N=301) arms of the HERA trial. The primary 
analysis endpoint was disease-free survival (DFS). Biomarkers were examined as continuous or 
categorical variables (pre-defined cutoffs). Interaction terms between biomarkers and treatment 
were assessed in multivariate Cox models adjusted for variables of clinical interest. 
Results: A significant interaction was detected between p27 and treatment (adjusted p=0.0049). 
Trastuzumab effect was significant in the p27 low subgroup (≤70% p27-positive tumor cells; 
N=318). HR Comb Trast vs. Obs 0.44, 95% CI: 0.29-0.65 (p<0.001). No trastuzumab effect was 
observed in the p27 high subgroup N=435; HR Comb Trast vs. Obs 0.97, 95% CI: 0.66-1.44, p=0.89), 
indicating that these patients derived little or no benefit from trastuzumab treatment. A 
prognostic effect of p27 on DFS was observed, with p27 high patients experiencing half the 
hazard of a DFS event compared to low ones (HR p27 High vs. Low 0.49, 95% CI: 0.32-0.75). 
TOP2A, Ki67 and cyclin D1, as categorical variables were not predictive, whereas cyclin D1 as 
continuous variable was predictive of trastuzumab benefit. 
Conclusions: In TransHERA, HER2-positive early breast cancer patients with low p27 
expression in their tumors benefited from trastuzumab treatment, whereas patients with high p27 
expression did not.  
 6 
Introduction 
Amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) 
oncogene and oncoprotein, respectively, occurs in about 15-20% of primary breast cancers. 
Patients with HER2-positive breast cancer benefit from treatment with anti-HER2 therapies 
including the monoclonal antibody trastuzumab (1,2). In the adjuvant setting, pivotal randomized 
clinical trials including the HERceptin Adjuvant (HERA) trial (1) showed that 1 year is the 
optimal duration for trastuzumab therapy in these patients (3). Despite the improvements of 
outcome achieved by anti-HER2 therapies, clinical resistance to trastuzumab remains a 
significant problem; long-term follow up indicates that a significant proportion of patients with 
early HER2-positive breast cancer will experience recurrence of their disease (4). The overall 
objective of TransHERA, the translational research sub-study of HERA, was to identify markers 
that can predict sensitivity or resistance to adjuvant trastuzumab therapy. 
Some clinical parameters, including histologic type and tumor stage are associated with the 
magnitude of benefit from adjuvant trastuzumab because of their relationship with prognosis but 
they do not relate to proportional benefit from trastuzumab (5). We have reported that HER2-
positive early breast cancers that are estrogen receptor (ER)-positive by immunohistochemistry with 
low HER2:CEP17 FISH ratio, or with higher mRNA expression of ESR1 levels derived significantly 
less benefit from adjuvant trastuzumab after chemotherapy in TransHERA (6). 
Several mechanisms of resistance to HER2 blockade have been described to date including 
activation of the phosphatidylinositol-3-kinase (PI3K) pathway (7,8). Cell cycle regulators have 
also been suggested to predict resistance or response to trastuzumab treatment (9,10). Cyclins, 
their associated cyclin-dependent kinases (CDKs), and CDK inhibitory proteins play a central 
role in cell cycle progression and may also affect response to trastuzumab (10). In addition, 
topoisomerase 2-alpha (TOP2A) alterations may also have the potential to act as a predictive 
biomarker of trastuzumab benefit (11,12). 
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In this study, we evaluated the prognostic/predictive value of p27, cyclin D1, TOP2A, and Ki67 
protein expression in patients with HER2-positive primary breast cancer who were enrolled in 
the HERA and participated in TransHERA. 
 
 
Patients and Methods 
Study design and participants 
The TransHERA sub-study included patients who participated in the HERA study (Breast 
International Group [BIG] 01-01-ClinicalTrials.gov NCT00045032), an international, intergroup, 
open-label, phase III randomized study enrolling 5102 women with HER2-positive 
(overexpressed or amplified) primary breast cancer (1), and who consented to evaluation of their 
tumor tissue for research purposes. All patients had at least 4 courses of adjuvant standard 
chemotherapy, and were randomized to one year or two years of adjuvant trastuzumab 
administered intravenously every 3 weeks, or to observation (no trastuzumab arm). The 
observation patients were allowed to selectively crossover to trastuzumab (either 1 or 2 year), if 
they were alive and disease free as of May 16
th
 2005, based on the significant benefit in disease-
free survival (DFS) for patients treated with 1-year trastuzumab versus observation shown at the 
first interim analysis. The study was conducted according to HERA master and Trans-HERA 
sub-study protocols; with adherence to country specific ethics, regulatory requirements and 
REMARK recommendations (13). 
 
 
Specimen collection and immunostaining for biomarkers 
Formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks were obtained at the time of 
surgery before adjuvant therapy. Paraffin blocks were stored at room temperature and were 
identifiable only by an identification number assigned to each patient at randomization. 
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Tissue microarrays were constructed with a manual tissue arrayer (MTA-1; Beecher Instruments, 
Sun Prairie, Wisconsin, USA) using 600 µm cores. Immunohistochemistry was performed and 
evaluated in the Austrian Breast cancer Study Group (ABCSG) central research laboratory at the 
Medical University of Vienna (p27, TOP2A, cyclin D1) and at the Royal Marsden Hospital, 
London (Ki67) by means of standard protocols. 
Briefly, tissue microarray sections were deparaffinized and rehydrated. After heat-induced 
epitope retrieval in 10 mM citrate buffer (pH 6·0) for 10 minutes, the tissue sections were 
incubated at room temperature with the particular monoclonal antibodies specific for p27 (clone 
SX53G8; Dako, Glostrup, Denmark; dilution 1:100), TOP2A (Ki-S1; Thermo Scientific; dilution 
1:200), cyclin D1 (SP4; NeoMarkers; dilution 1:100), and Ki67 (MIB1; Dako, Glostrup, 
Denmark; dilution 1:40). Antibody binding was detected by means of the UltraVision LP 
detection system (p27, TOP2A, cyclin D1; Lab Vision Corporation) or with the Dako REAL 
Detection System (Ki67, Dako) according to the manufacturer’s recommendations. Color 
development was performed by 3-3’-diaminobenzidine and counterstaining by hematoxylin. 
Immunostaining was evaluated without knowledge of the patients’ clinical data. All invasive 
tumor cells on each core were evaluated. Interpretation of the results was limited to the invasive 
part of the tumor and only nuclear staining was scored as positive. The results were documented 
as the percentage of stained nuclei regardless of staining intensity. 
 
Statistical analyses 
The primary analysis was an intention-to-treat analysis. To take into account selective crossover, 
additional analyses were performed. These included a censored, an IPCW (Inverse Probability 
Censored Weighting), and an early events analysis. In the censored analysis, no further follow-up 
is taken into account for observation patients that crossed over to a trastuzumab arm, at the time 
of crossing over. In the IPCW analysis, the additional follow-up for these patients is substituted 
by weighting appropriately the patients who did not cross over. In the early events analysis, only 
 9 
events occurring up to 2.2 years of median follow-up were taken into account. These events, 
important in the context of translational research, occurred at a time when crossover was 
minimal. 
The primary endpoint of the study was DFS, defined as time from randomization to first 
occurrence of local, regional, distant recurrence, contralateral breast cancer including ductal 
carcinoma in situ (DCIS), second non-breast malignant disease or death from any cause. Overall 
survival (OS) was a secondary endpoint, defined as the time from randomization to death from 
any cause. In the present analysis the 1-year and 2-year trastuzumab arms were combined into a 
single arm (3). 
Survival outcomes were obtained from the HERA database with clinical cut-off date the 12
th
 of 
April 2012 and a median follow-up time of 8 years (IQ range with interquartile range). The 
representativeness of the present cohort, with respect to the original HERA population was 
explored via the comparison of patients’ baseline characteristics and outcomes. 
Fisher’s exact and Mantel-Haenszel or Kruskal-Wallis tests were used in order to explore 
potential differences between groups. The distributions of the markers were shown graphically 
via histograms, whereas their associations were explored by scatter plots, box-plots, and the 
Spearman correlation coefficient. In all exploratory analyses, results with a two-sided p-value 
less than 0.05 were considered significant. 
Cox proportional hazards regression for DFS and OS, was the main analysis tool in order to 
assess prognostic or predictive effect of the markers. Marker and treatment effects were added 
into the models, along with their interaction terms. Hazard ratios (HRs), along with 
corresponding 95% confidence intervals (CIs), were used to show the relationship between 
markers and outcome. The observed differences in hazards between groups are presented through 
Kaplan-Meier curves. In multivariate models, adjustment for variables of clinical interest [age, 
pathological tumor size, progesterone receptor (PgR) local, tumor grade, menopausal status, 
nodal status, prior-(neo) adjuvant chemotherapy, ECOG performance status, race, region, ER 
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local and ESR1 (categorization based on tertiles) (6) main and predictive effects] was performed, 
and the best model was chosen by the backward selection method with removal criterion a p-
value>0.10. Departures from the proportional hazards assumption were assessed based on the 
Schoenfeld residuals (14). The False Discovery Rate (FDR) method was implemented to account 
for multiple testing (15). 
Biomarkers were analyzed either as continuous or as categorical variables, based on the 
following prospectively specified categorization scheme: TOP2A percent: ≤5 versus >5, Ki67 
according to tertiles, cyclin D1 percent: ≤10 versus >10, p27 percent: ≤70 versus >70 (12,16-18). 
Whenever a continuous variable showed a significant interaction with treatment not translated 
when the marker was categorized in two groups, further exploration using tertiles for the 
corresponding marker was performed. 
 
Results 
Study Population 
Out of the 5099 HERA patients (excluding three patients due to missing informed consent 
documentation), there were 1162 participating in TransHERA. From these, 862 patients (17% of 
the whole study population) had available information on the protein expression on at least one 
of the following biomarkers: TOP2A, Ki67, cyclin D1, or p27. 
Patient and tumor baseline characteristics, as well as information on DFS and OS for the current 
analysis cohort and the remainder of the HERA population are shown in Tables S1-4. Tumor 
size, ER measured locally, race, region, and prior neoadjuvant chemotherapy were baseline 
characteristics differing substantially between the TransHERA group and the remainder of 
HERA cohort. For both DFS and OS, the observed magnitude of the trastuzumab benefit in the 
TransHERA group is similar to that detected in the HERA cohort. In the current analysis cohort, 
the treatment effect is significant for DFS, whereas for OS the indicated beneficial effect does 
not reach significance, probably due to the small event number (DFS: TransHERA group: HR 
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Comb Trast vs. Obs = 0.74, 95% CI: 0.57-0.95, Remainder of HERA cohort:HR Comb Trast vs. Obs = 0.76, 
95% CI 0.68-0.85; OS: TransHERA group HR Comb Trast vs. Obs =0.73, 95% CI: 0.51-1.03, 
Remainder of HERA cohort: HR Comb Trast vs. Obs= 0.75, 95% CI: 0.65-0.86). 
In the current analysis cohort, 301 patients were randomized to the observation arm and 561 to 
the combined trastuzumab arm (1- or 2-year trastuzumab). All characteristics of the patients were 
balanced between the two treatment groups (Table 1). Out of the 248 observation patients 
eligible to cross over, 188 (74.3%) switched to trastuzumab treatment. 
 
Biomarker distributions and associations  
Frequency distribution on biomarker categories overall and according to treatment arms are 
shown in Table 2, while distributions of TOP2A, Ki67, cyclin D1, and p27, used as continuous 
variables are presented in figures S1A-D. No difference in the expression of the biomarkers was 
seen by treatment allocation.  
Significant positive associations were detected for TOP2A with Ki67 (rSpearman =0.47, p<0.001), 
cyclin D1 (rSpearman =0.22, p<0.001), p27 (rSpearman=0.12, p=0.0017); and cyclin D1 with Ki67 
(rSpearman =0.15, p<0.001), and p27 (rSpearman =0.56, p<0.001), (Figures S2A-C and S3A-B). When 
biomarkers were treated as categorical variables, all associations remained significant except the 
association between p27 and TOP2A. In addition, a significant association between p27 and Ki67 
(Fisher’s exact p=0.043) was observed. 
 
Biomarker association with baseline characteristics 
Significant associations were observed between p27 and ER, PgR and tumor grade (p<0.001). 
P27 high cases are more frequent in ER positive (76.3% vs. 39.3% for ER negative), PgR 
positive (76.7% vs. 47.3% for PgR negative) and tumor grade 2 groups (67.4% vs. 53.1% for 
grade 3). Higher cyclin D1 values are more frequent in ER and PgR positive subgroups (31.3% 
vs. 11.7% for ER negative and 30.9% vs. 14.3% for PgR negative, p<0.001 for both). Ki67 is 
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significantly associated with PgR (p=0.017), tumor grade (p<0.001), race (p=0.0039) and region 
(p<0.001). No associations between Topo2A and any baseline characteristic was detected. 
 
Biomarker associations with outcome 
A total of 249 DFS events (28.9%) and 129 (15.0%) deaths were observed in our cohort. The 8-
year DFS and OS estimates were 70.5% (95% CI: 67.3%-73.6%) and 84.5% (95% CI: 82.0%-
87.0%), respectively. TOP2A, Ki67 and cyclin D1 when used as categorical variables were 
neither prognostic nor predictive of adjuvant trastuzumab benefit (adjusted interaction p=0.80, 
0.81 and 0.17 respectively; Figures 1 A-B). However, a significant interaction was detected 
between p27 classified as categorical variable and treatment (interaction p=0.036; FDR p=0.17; 
Table S5). This interaction was also significant after adjusting for variables of clinical interest, 
i.e. (p=0.0049, FDR p=0.045; Figure 1D & 2, Table S6; significant variables: region, nodal status 
and pathological tumor size). Patients in the observation arm classified as p27 high (>70% p27-
positive tumor cells) experience half the hazard of a DFS event compared to patients in the p27 
low group (HRp27 high vs. low =0.49; 95% CI: 0.32-0.75, p=0.012; Table S6). No p27 effect is 
observed in the trastuzumab arm HRp27 high vs. low =1.09, 95% CI: 0.77-1.54, p=0.64; Table S6). 
For patients classified as p27 low, a significant treatment effect was observed (HR Comb Trast vs. Obs 
=0.44, 95% CI: 0.29-0.65, p<0.001), while the treatment effect was not found significant for 
patients in the p27 high group (HR Comb Trast vs. Obs =0.97, 95% CI: 0.66-1.44, p=0.88). The 
predictive ability of p27 was maintained when the remaining three markers were included in the 
model (adjusted interaction p=0.0039; FDR p=0.095), or when the predictive effect of ER Local 
or ERS1 gene expression was included in the model (Tables S7-8).  
When biomarkers were treated as continuous variables, the only marker found to have a 
significant predictive effect on DFS was cyclin D1 (interaction p=0.006; Table S10). This effect 
remained statistically significant after adjusting for clinical parameters (p=0.0046, FDR p=0.045; 
Table S10). Higher levels of cyclin D1 were significantly associated with better DFS in the 
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observation arm (HR =0.96, 95% CI 0.94-0.99, p=0.0082) but not in the trastuzumab arm (HR 
=1.01, 95% CI: 0.99-1.02, p=0.31). Inference remains the same when accounting for the 
remaining three markers (adjusted p=0.0042, FDR p=0.05), or ER and ESR1 predictive effects 
(Tables S11-12). 
To further investigate the predictive ability of cyclin D1, a categorization based on tertiles was 
also considered (low, intermediate and high; p=0.013, FDR p=0.078; Figure 1C). Adjusting for 
baseline characteristics, a significant treatment benefit was detected for cyclin D1 for the low and 
intermediate groups (low: HR Comb Trast vs. Obs =0.43, 95% CI: 0.25- 0.74, p=0.0024 and 
intermediate HR Comb Trast vs Obs 0.57, 95% CI: 0.36-0.90, p=0.015). For cyclin D1 high category, 
no treatment benefit is detected (HR Comb Trast vs. Obs =1.08, 95% CI: 0.67-1.74, p=0.75). This 
corresponds to not observing any effect of cyclin D1 in the trastuzumab arm, while in the 
observation arm, the hazard of a DFS event was found significantly lower for the high group 
patients as compared to the low group patients (HR high vs. low =0.51, 95% CI: 0.29-0.89, p=0.017). 
The above findings on cyclin D1 did not change after adjusting for the remaining three markers. 
In particular, the interaction term between treatment and cyclin D1 (high versus low) was found 
significant (p=0.010; FDR p=0.068). 
No significant interaction was detected between treatment and any of the four biomarkers (both 
as continuous and categorical variable), with respect to OS. The results of the early events, 
censored and IPCW analyses did not lead to different conclusions from the ITT analysis. 
 
 
Discussion 
Results of the HERA trial demonstrated that one year of adjuvant trastuzumab treatment of early-
stage HER2-positive breast cancer patients provides a significant DFS and OS benefit compared 
with observation and the degree of benefit was similar to that with 2 years’ trastuzumab. This has 
resulted in one year of trastuzumab being the standard of care for patients with HER2-positive 
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early breast cancer (1,3). It also allowed us to analyze the outcome data from the 1 year and 2 
year trastuzumab arms of HERA as a single treatment arm. Our study is a step forward in 
establishing the impact of molecular biomarkers on the outcome of a large group of patients in 
this study cohort. Of great importance we report for the first time within the context of an 
adjuvant randomized trastuzumab trial that the positive and negative cell cycle regulators p27 
and cyclin D1 respectively have predictive value in HER2-positive early breast cancer: only 
patients with low p27 expression or lower levels of cyclin D1 expression benefited from 
trastuzumab treatment in the TransHERA cohort. 
Strengths of this study were the randomized design of the clinical trial from which the patients 
were derived, the relatively large size of the TransHERA population, the biomarker analysis 
using validated assays in a central laboratory and the data analyses being conducted on a formal 
statistical analysis plan that included adjustment on standard prognostic variables. A weakness is 
that the TransHERA group was only a modest proportion of the HERA trial and although the 
outcome data were similar in those patients included or not included in TransHERA it cannot be 
concluded that our findings apply fully across the whole trial population. In addition, although 
the markers were selected as potential candidate markers on the basis of previous findings, the 
predictive role of p27 and cyclin D1 still requires validation before being accepted as clinically 
valid and worthy of investigation for clinical utility. 
We applied a previously defined cut-off for p27 positivity (high 70% p27-positive tumor cells). 
This had previously been used to assess the clinical relevance of p27 in postmenopausal hormone 
receptor-positive breast cancer patients who received tamoxifen for 5 years in Austrian Breast 
and Colorectal Cancer Study Group Trial 06 (17). In that retrospective analysis, women with 
high p27 expression had a significantly longer DFS and OS as compared to women with low p27 
expression; this finding is similar to what we report in this HER2-positive breast cancer cohort, 
where p27 showed strong favorable prognostic significance in the observation group. 
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It has previously been described that induction of p27, a CDK inhibitor functioning as distal 
downstream regulator of several oncogenic signaling pathways, is one of the key modes of action 
of HER2-targeting antibodies in breast cancer (19-22), with an increase in p27 thought to cause 
proliferating cells to exit the cell cycle and thereby undergo apoptosis (23). It may be that breast 
cancer patients with HER2-positive, p27 low expressing tumors benefit more from trastuzumab 
because the effect of p27 up-regulation may be greater in these patients compared to patients 
whose tumors have p27 high expression. Interestingly, down-regulation of p27 has been 
associated with trastuzumab resistance in breast cancer cells (9) and trastuzumab-resistant cells 
have been reported to have decreased levels of p27 and exogenous addition of trastuzumab to 
increase trastuzumab sensitivity (9). Thus it seems likely that decreased p27 levels in the tumors 
of trastuzumab- resistant patients are mediated by different mechanisms compared to low p27 
expression in trastuzumab-naive patients. One potential mechanism in trastuzumab-resistant cells 
could be overexpression of insulin-like growth factor I receptor (IGF-IR) (24). It has been shown 
that the mechanism by which IGF-IR confers resistance to trastuzumab involves increased 
degradation of p27 by the ubiquitin/proteasome degradation machinery (24). Thus sensitivity and 
resistance to trastuzumab in HER2-overexpressing cells is critically dependent on p27 levels. 
Only limited information on the clinical role of p27 as a predictive marker for trastuzumab 
therapy in breast cancer is available in the literature. In a Japanese trial, the association of p27 
and other biomarkers with pathological complete response (pCR) and survival was studied in 
women with HER2-positive breast cancer who received neo-adjuvant trastuzumab-based 
chemotherapy (25). In this study, the pCR rate was significantly higher in patients whose tumors 
had low expression of p27 (defined as <75% p27-positive tumor cells) compared to patients with 
high p27 expression (71% versus 50%, respectively, p=0.025) (25). This is in line with our 
observation that patients with low p27 expression in their tumors benefit more from trastuzumab 
treatment than patients with high p27 expression in their tumors. High grading, low ER, low PgR 
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and high Ki67 also predicted pCR in the Japanese patient cohort. However, we could not confirm 
the predictive value of these biomarkers in TransHERA patients. 
If the result that only HER2-positive early breast cancer patients with low p27 expression in their 
tumors benefit from trastuzumab treatment is validated, this finding may help to optimize the 
adjuvant treatment of patients with HER2-positive breast cancer in the future. 
In summary, we have analyzed p27 protein expression in early stage HER2-positive breast 
cancers from women who had been enrolled into the HERA trial. We have demonstrated that, by 
using a predefined cut-off, low p27 expression may be associated with benefit from adjuvant 
trastuzumab treatment. 
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Figure Legends 
 
Figure 1 Survival curves for disease-free survival (DFS) according to TOP2A (A), Ki67 (B), 
cyclin D1 (C), and p27 expression (D) in the observation arm and the trastuzumab arm. The 
adjusted interaction P values and the 8-year DFS rates are reported. 
 
Figure 2 Analyses of disease-free survival according to biomarker subgroups. The hazard ratios 
(with 95 percent confidence intervals) are for the patients assigned to trastuzumab arm, as 
compared with those assigned to observation arm. The adjusted interaction P values are reported. 
CI denotes confidence interval.  
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Table 1: Summary of baseline characteristics for current analysis cohort, overall and by 
treatment arm 
 (*)Mantel-Haenszel, (∱)Fisher’s exact, (∞)Excluding category “Missing”, (£)Excluding category “Unknown”, ( ©)Excluding category 
“Uncertain”, ( ≠)Excluding category “Not Assessed”  
 
 
 Baseline characteristics 
Observation 
(N=301) 
Combined 
Trastuzumab 
(N=561) 
Total 
(N=862) 
p-value 
Age in yrs  
Median  50 50 50  
<35 14 (4.65%) 42 (7.49%) 56 (6.50%) 0.61* 
35-49 134 (44.52%) 238 (42.42%) 372 (43.16%)  
50-59 103 (34.22%) 185 (32.98%) 288 (33.41%)  
≥60 50 (16.61%) 96 (17.11%) 146 (16.94%)  
Pathological Tumor Size  
Median in mm 20.0 22.0 21.0  
0-2 cm 150 (49.83%) 261 (46.52%) 411 (47.68%) 0.49* 
>2-5 cm 134 (44.52%) 261 (46.52%) 395 (45.82%) 0.29*
,∞
 
>5 cm 13 (4.32%) 31 (5.53%) 44 (5.10%)  
Missing 4 (1.33%) 8 (1.43%) 12 (1.39%)  
PgR Local  
Negative (-) 177 (58.80%) 307 (54.72%) 484 (56.15%) 0.47∱
,£
 
Positive (+) 96 (31.89%) 202 (36.01%) 298 (34.57%)  
Unknown 28 (9.30%) 52 (9.27%) 80 (9.28%)  
ER Local  
Negative (-) 160 (53.16%) 277 (49.38%) 437 (50.70%) 0.32∱ 
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 Baseline characteristics 
Observation 
(N=301) 
Combined 
Trastuzumab 
(N=561) 
Total 
(N=862) 
p-value 
Positive (+) 141 (46.84%) 284 (50.62%) 425 (49.30%)  
Tumor Grade  
G1 7 (2.33%) 8 (1.43%) 15 (1.74%) 0.42* 
G2 99 (32.89%) 174 (31.02%) 273 (31.67%)  
G3 191 (63.46%) 375 (66.84%) 566 (65.66%)  
GX 4 (1.33%) 4 (0.71%) 8 (0.93%)  
Menopausal status  
Premenopausal 39 (12.96%) 61 (10.87%) 100 (11.60%) 0.61∱ 
Postmenopausal 132 (43.85%) 245 (43.67%) 377 (43.74%) 0.48∱
,©
 
Uncertain 130 (43.19%) 255 (45.45%) 385 (44.66%)  
Nodal status  
Not assessed (neoadjuvant chemotherapy) 11 (3.65%) 38 (6.77%) 49 (5.68%) 0.18* 
Negative 102 (33.89%) 186 (33.16%) 288 (33.41%) 0.65*
, ≠
 
1-3 88 (29.24%) 169 (30.12%) 257 (29.81%)  
≥4 100 (33.22%) 168 (29.95%) 268 (31.09%)  
Ethnicity  
Caucasian 281 (93.36%) 517 (92.16%) 798 (92.58%) 0.46∱ 
Oriental 19 (6.31%) 37 (6.60%) 56 (6.50%)  
Other 1 (0.33%) 7 (1.25%) 8 (0.93%)  
Region  
Western and Northern Europe, Canada, 
South Africa, Australia, New Zealand 
248 (82.39%) 449 (80.04%) 697 (80.86%) 0.88∱ 
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 Baseline characteristics 
Observation 
(N=301) 
Combined 
Trastuzumab 
(N=561) 
Total 
(N=862) 
p-value 
Asia Pacific, Japan 16 (5.32%) 33 (5.88%) 49 (5.68%)  
Eastern Europe 30 (9.97%) 65 (11.59%) 95 (11.02%)  
Central and South America 7 (2.33%) 14 (2.50%) 21 (2.44%)  
Prior (neo)adjuvant chemotherapy  
No anthracyclines 18 (5.98%) 30 (5.35%) 48 (5.57%) 0.90∱ 
Anthracyclines, no taxanes 216 (71.76%) 401 (71.48%) 617 (71.58%)  
Anthracyclines and taxanes 67 (22.26%) 130 (23.17%) 197 (22.85%)  
ECOG Performance Status  
0 270 (89.70%) 512 (91.27%) 782 (90.72%) 0.46∱ 
1 31 (10.30%) 49 (8.73%) 80 (9.28%)  
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Table 2: Biomarker’s level distributions, overall and by treatment arm 
Fisher’s exact test computed, ⊕ Excluding category “Missing” 
 
Biomarker level  
Observation 
(N=301) 
Combined 
trastuzumab 
(N=561) 
Total 
(N=862) 
p-value 
p27  
Low (≤ 70) 113 (37.54%) 205 (36.54%) 318 (36.89%) 0.46 
High (>70) 145 (48.17%) 290 (51.69%) 435 (50.46%) 0.54⊕ 
Missing 43 (14.29%) 66 (11.76%) 109 (12.65%)  
Cyclin D1  
Low (≤10) 207 (68.77%) 388 (69.16%) 595 (69.03%) 0.41 
High (>10) 52 (17.28%) 110 (19.61%) 162 (18.79%) 0.58⊕ 
Missing 42 (13.95%) 63 (11.23%) 105 (12.18%)  
TOP2A  
Low (≤ 5) 119 (39.53%) 234 (41.71%) 353 (40.95%) 0.77 
High (>5) 140 (46.51%) 256 (45.63%) 396 (45.94%) 0.65⊕ 
Missing 42 (13.95%) 71 (12.66%) 113 (13.11%)  
Ki67  
0≤Ki67<13.2 92 (30.56%) 169 (30.12%) 261 (30.28%) 0.67 
13.2≤ Ki67<24.6 88 (29.24%) 171 (30.48%) 259 (30.05%) 0.93⊕ 
Ki67≥24.6 89 (29.57%) 175 (31.19%) 264 (30.63%)  
Missing 32 (10.63%) 46 (8.20%) 78 (9.05%)  
 
